Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.REGENX Biosciences and Voyager Therapeutics have entered into a license agreement for use of REGENX's proprietary NAV vectors to develop and commercialize gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS), Friedreich's ataxia (FA) and Huntington's disease (HD).
Subscribe to our email newsletter
As part of the deal, REGENX has granted Voyager a non-exclusive worldwide license, as well as sublicensing rights, to its NAV vectors for the treatment of ALS, FA and HD.
In return, REGENX will receive an undisclosed upfront payment, ongoing fees, milestone payments, and royalties on net sales of products incorporating NAV vectors.
REGENX is also eligible to receive a share of certain sublicensing revenues.
REGENX president and CEO Ken Mills said the license agreement serves as further validation of the company’s proprietary NAV vector technology platform, and is an important step toward the successful development of NAV-based gene delivery treatments for patients afflicted with the serious and debilitating rare diseases to which Voyager is committed.
"As the leader in next-generation AAV gene therapy, REGENX is pleased to be collaborating with Voyager, which is well-positioned to develop innovative treatments through the application of our NAV technology," Mills said.
Voyager interim CEO Mark Levin said the company is the leading AAV gene therapy firm focused on developing life-changing treatments for patients with devastating CNS disorders.
"We are committed to advancing the AAV gene therapy field via broad-based investment in a number of key technological areas," Levin said.
"In addition to providing a valuable addition to Voyager’s intellectual property portfolio, the rights to use REGENX’s NAV vectors will position us to rapidly advance the development of breakthrough CNS gene therapies."